COVID-19 and COPD: a narrative review of the basic science and clinical outcomes
The 2019 coronavirus disease (COVID-19) pandemic is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Clinical outcomes, including mortality, are worse in males, older individuals and patients with comorbidities. COPD patients are included in shielding strategies due to their s...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2020-11-01
|
| Series: | European Respiratory Review |
| Online Access: | http://err.ersjournals.com/content/29/158/200199.full |
| _version_ | 1818938054518243328 |
|---|---|
| author | Andrew Higham Alexander Mathioudakis Jørgen Vestbo Dave Singh |
| author_facet | Andrew Higham Alexander Mathioudakis Jørgen Vestbo Dave Singh |
| author_sort | Andrew Higham |
| collection | DOAJ |
| description | The 2019 coronavirus disease (COVID-19) pandemic is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Clinical outcomes, including mortality, are worse in males, older individuals and patients with comorbidities. COPD patients are included in shielding strategies due to their susceptibility to virus-induced exacerbations, compromised pulmonary function and high prevalence of associated comorbidities. Using evidence from basic science and cohort studies, this review addresses key questions concerning COVID-19 and COPD. First, are there mechanisms by which COPD patients are more susceptible to SARS-CoV-2 infection? Secondly, do inhaled corticosteroids offer protection against COVID-19? And, thirdly, what is the evidence regarding clinical outcomes from COVID-19 in COPD patients? This up-to-date review tackles some of the key issues which have significant impact on the long-term outlook for COPD patients in the context of COVID-19. |
| first_indexed | 2024-12-20T06:01:45Z |
| format | Article |
| id | doaj.art-8482c72645fc46c2934f1bf7ab638ef0 |
| institution | Directory Open Access Journal |
| issn | 0905-9180 1600-0617 |
| language | English |
| last_indexed | 2024-12-20T06:01:45Z |
| publishDate | 2020-11-01 |
| publisher | European Respiratory Society |
| record_format | Article |
| series | European Respiratory Review |
| spelling | doaj.art-8482c72645fc46c2934f1bf7ab638ef02022-12-21T19:50:54ZengEuropean Respiratory SocietyEuropean Respiratory Review0905-91801600-06172020-11-012915810.1183/16000617.0199-20200199-2020COVID-19 and COPD: a narrative review of the basic science and clinical outcomesAndrew Higham0Alexander Mathioudakis1Jørgen Vestbo2Dave Singh3 Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK The 2019 coronavirus disease (COVID-19) pandemic is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Clinical outcomes, including mortality, are worse in males, older individuals and patients with comorbidities. COPD patients are included in shielding strategies due to their susceptibility to virus-induced exacerbations, compromised pulmonary function and high prevalence of associated comorbidities. Using evidence from basic science and cohort studies, this review addresses key questions concerning COVID-19 and COPD. First, are there mechanisms by which COPD patients are more susceptible to SARS-CoV-2 infection? Secondly, do inhaled corticosteroids offer protection against COVID-19? And, thirdly, what is the evidence regarding clinical outcomes from COVID-19 in COPD patients? This up-to-date review tackles some of the key issues which have significant impact on the long-term outlook for COPD patients in the context of COVID-19.http://err.ersjournals.com/content/29/158/200199.full |
| spellingShingle | Andrew Higham Alexander Mathioudakis Jørgen Vestbo Dave Singh COVID-19 and COPD: a narrative review of the basic science and clinical outcomes European Respiratory Review |
| title | COVID-19 and COPD: a narrative review of the basic science and clinical outcomes |
| title_full | COVID-19 and COPD: a narrative review of the basic science and clinical outcomes |
| title_fullStr | COVID-19 and COPD: a narrative review of the basic science and clinical outcomes |
| title_full_unstemmed | COVID-19 and COPD: a narrative review of the basic science and clinical outcomes |
| title_short | COVID-19 and COPD: a narrative review of the basic science and clinical outcomes |
| title_sort | covid 19 and copd a narrative review of the basic science and clinical outcomes |
| url | http://err.ersjournals.com/content/29/158/200199.full |
| work_keys_str_mv | AT andrewhigham covid19andcopdanarrativereviewofthebasicscienceandclinicaloutcomes AT alexandermathioudakis covid19andcopdanarrativereviewofthebasicscienceandclinicaloutcomes AT jørgenvestbo covid19andcopdanarrativereviewofthebasicscienceandclinicaloutcomes AT davesingh covid19andcopdanarrativereviewofthebasicscienceandclinicaloutcomes |